Truth Seeker
New Member
An FDA advisory panel has voted unanimously not to recommend sale in the U.S. of rimonabant, a widely anticipated antiobesity drug, the New York Times reports.
The drug, available in 37 countries, was rejected "because of worries that it causes neurological and psychiatric problems and increases the risk of suicide," according to the newspaper.
Rimonabant is a cannabinoid-receptor blocker. In clinical studies, it had shown favorable effects not only on weight loss but also on fasting glucose, HDL cholesterol, and triglycerides.
Source: FDA Advisory Panel Rejects Obesity Drug - Physician's First Watch
The drug, available in 37 countries, was rejected "because of worries that it causes neurological and psychiatric problems and increases the risk of suicide," according to the newspaper.
Rimonabant is a cannabinoid-receptor blocker. In clinical studies, it had shown favorable effects not only on weight loss but also on fasting glucose, HDL cholesterol, and triglycerides.
Source: FDA Advisory Panel Rejects Obesity Drug - Physician's First Watch
